Tirzepatide ZPHC — 37.5 mg (5 vials × 7.5 mg)

Tirzepatide – 5 vials × 7.5 mg (total 37.5 mg)

• Dual GLP-1 / GIP agonist: powerful incretin peptide that supports significant weight-loss and improved glycaemic control.
• Sustained once-weekly action: long half-life keeps appetite and blood-sugar in check for a full 7 days.
• Lyophilised 7.5 mg vials: reconstitute each vial with 1 ml bacteriostatic water → 7.5 mg/ml solution (0.1 ml ≈ 0.75 mg).
• Dosing guide (research): start 2.5 mg once weekly, titrate to 5–7.5 mg over 4–8 weeks; typical study length 12–24 weeks.
• Pharma-grade QC: ZPHC batches ≥ 99 % purity, endotoxin-free; tamper-evident box with scratch-code authenticity.
• Cold-chain shipping • discreet packaging • worldwide tracked delivery.